Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 47Glioblastoma 47Breast Neoplasms 40Esophageal Neoplasms 36Rectal Neoplasms 35Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 33Head and Neck Neoplasms 29Squamous Cell Carcinoma of Head and Neck 26Brain Neoplasms 23Pancreatic Neoplasms 22Neoplasms 19Uterine Cervical Neoplasms 17Oropharyngeal Neoplasms 16Neoplasm Metastasis 16Gliosarcoma 16Esophageal Squamous Cell Carcinoma 16Glioma 15Sarcoma 14Melanoma 14Stomach Neoplasms 12Adenocarcinoma Of Esophagus 12Lymphoma, Follicular 9Carcinoma, Squamous Cell 9Mouth Neoplasms 8Lymphoma, B-Cell, Marginal Zone 8Anus Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Acute 7Endometrial Neoplasms 7

Interventions

Gemcitabine 2Cystectomy 2Cisplatin 2transplatin 1pembrolizumab 1pegfilgrastim 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Platinum 1Chemoradiotherapy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Infiltrating Bladder Urothelial Carcinoma × Radiation × Clear all
NCT03419130 2018-12-07

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

University of California, San Francisco

Phase 2 Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡